Louis G. Lange, M.D., Ph.D. Symposium on Academia-Industry Synergy at the Forefront of Translational Medicine
To view this year's Lange Symposium click here.
We are very excited to announce the Symposium on Academia-Industry Synergy at the Forefront of Translational Medicine to be held on December 10th, 2013. This event will be held in honor of our alum, Lou Lange, MD, PhD, currently General Partner of Asset Management and founder of CV Therapeutics (see bio below). Dr. Lange has been a great supporter of our students and our program. The Symposium will aim to develop new ideas for synergy between academia and industry to enhance the translation of biomedical discoveries to the clinic as well as expose students and other trainees to cutting edge approaches in experimental therapeutics. Industry panelists include Peter Kim, PhD, (formerly Merck) and Michael Vincent, MD, PhD, Pfizer. Academic panelists include Sangeeta Bhatia, MD-PhD, MIT/HMS/BWH, Peter Sorger, PhD, HMS, and Isaac Kohlberg, Chief Technology Development Officer, Harvard University. Dean Flier will serve as the moderator. Panelists will be asked to present their perspectives on coordinating efforts between academia and industry and to comment on how their career paths prepared them for a career in translational medicine and therapeutics. Following the Symposium, the MD-PhD Program will be hosting a dinner for its students and other invited guests where Dr. Lange will provide personal reflections on his career bridging academia and industry. Co-sponsorship includes Harvard University Office of Technology Development, HMS Office of Graduate Education and Global Programs, HMS Division of Medical Sciences, and Novartis.
Jeffrey S. Flier, M.D.
Dean of the Faculty of Medicine at Harvard University
Caroline Shields Walker Professor of Medicine at HMS
In 2007, Jeffrey S. Flier, M.D. was named the 21st Dean of the Faculty of Medicine at Harvard University, and the Caroline Shields Walker Professor of Medicine at HMS. Dr. Flier received a BS from City College of New York in 1968 and an MD from Mount Sinai School of Medicine in 1972, graduating with the Elster Award for Highest Academic Standing. Following residency training in internal medicine at Mount Sinai Hospital (1972-1974), Dr. Flier was a Clinical Associate at the National Institutes of Health. In 1978, he joined the Faculty of Medicine at HMS at Beth Israel Hospital serving as Chief of the Diabetes Unit and then chief of the hospital’s Endocrine Division. Dr. Flier is one of the country’s leading investigators and an authority in the molecular causes of obesity and diabetes. His research has produced major insights into the molecular mechanism of insulin action, the molecular mechanisms of insulin resistance in human disease, and the molecular pathophysiology of obesity. He has authored over 200 scholarly papers and reviews. Dr. Flier is an elected member of the Institutes of Medicine and a fellow of the American Academy of Arts and Sciences. The American Diabetes Association has honored Dr. Flier with the Eli Lilly Award, the Banting Medal (the ADA’s highest scientific honor) and the Albert Renold Award for outstanding achievements in the training of diabetes research scientists and the facilitation of diabetes research. Flier received the Edwin B. Astwood Award from the Endocrine Society, was awarded an Honorary Doctor of Science Degree from the University of Edinburgh, and in 2011 received the Rolf Luft Award for Metabolic Research from the Karolinska Institute in Sweden.
Peter Kim, PhD
Former President, Merck Research Laboratories
Peter S. Kim is a structural biologist known for discovering how proteins cause viral membranes to fuse with cells. He has designed novel compounds that stop membrane fusion by the AIDS virus, thereby preventing it from infecting cells, and has pioneered efforts to develop an HIV vaccine based on similar principles.
Dr. Kim was elected a member of the National Academy of Sciences in 1997. He is also an elected member of the Institute of Medicine and the American Academy of Arts and Sciences.
Dr. Kim was appointed president of Merck's Research Laboratories (MRL) in 2003 and was responsible for Merck's drug and vaccine research and development activities until 2013. During his tenure, Merck gained approval of more than 20 new medicines and vaccines. These include JANUVIA (sitagliptin), the first DPP-4 inhbitor for type 2 diabetes; GARDASIL (recombinant HPV quadrivalent vaccine), the first vaccine for prevention of cervical cancer; ISENTRESS (raltegravir), the first HIV integrase inhibitor; and VICTRELIS (boceprevir), the first hepatitis C protease inhibitor.
Prior to joining Merck, Dr. Kim was a Professor of Biology at Massachusetts Institute of Technology (MIT). He was also a Member of the Whitehead Institute and an Investigator of the Howard Hughes Medical Institute. His work has earned him numerous awards including the National Academy of Sciences Award in Molecular Biology, the Eli Lilly Award in Biological Chemistry, the Hans Neurath Award of the Protein Society, and the Samsung Foundation Ho-Am Prize in Basic Science.
Michael Vincent, MD, PhD
Vice President and Head of Clinical Research, Pfizer Inc
Michael Vincent, MD, PhD serves as Vice President and Head of Clinical Research for Pfizer’s BioTherapeutics’ R&D organization. As Head of Clinical Research, Michael is responsible for the planning and execution of BioTx Clinical Trials and for ensuring Precision Medicine strategies are successfully embedded in BioTx projects through proof of concept. His group also supports the clinical activities for the Centers for Therapeutic Innovation (CTI), Pfizer’s global partnership with academic medical centers. Prior to joining Pfizer, Michael was an Executive Medical Director for Amgen’s Medical Sciences division, where he was responsible for progression of therapeutic candidates globally in inflammation and neuroscience therapeutic areas through Phase 2 PoC. In addition to completing fellowships in rheumatology at both Brigham and Women’s Hospital and Fletcher Allen Health Care Medical Center of Vermont, Michael previously served as attending physician at Brigham and Women’s Hospital and as Instructor in Medicine at Harvard University.
Sangeeta Bhatia, MD-PhD
John J. and Dorothy Wilson Professor of Health Sciences and Technology (HST) and Electrical Engineering and Computer Science (EECS) at MIT
Dr. Bhatia is the John J. and Dorothy Wilson Professor of Health Sciences and Technology (HST) and Electrical Engineering and Computer Science (EECS) at MIT, and a Howard Hughes Medical Investigator. She also has appointments at Brigham & Women’s Hospital, Broad Institute, Institute for Medical Engineering & Science at MIT, Koch Institute for Integrative Cancer Research, and Harvard Stem Cell Institute. Her lab conducts research at the intersection of engineering, medicine, and biology to develop novel platforms for understanding, diagnosing and treating human disease. She has pioneered technologies for interfacing living cells with synthetic systems, enabling new applications in tissue regeneration, stem cell differentiation, medical diagnostics and drug delivery. Dr. Bhatia’s findings have produced human microlivers which model human drug metabolism, drug-induced liver disease, and interaction with human pathogens. With these platforms, she achieved the first high-throughput models that fully replicate the life cycles of hepatitis C and liver-stage human malaria. Her group also develops nanomaterial systems which assemble and communicate to interrogate and coordinately treat cancer.
Dr. Bhatia received her B.S. from Brown University, M.S. and Ph.D. from MIT, M.D. from Harvard and completed graduate and post-doctoral training at MGH. Prior to MIT, she held a tenured faculty position at UCSD, and worked at Pfizer, Genetics Institute, ICI Pharmaceuticals, and Organogenesis. Dr. Bhatia has published >150 manuscripts which were cited more than 3100 times in 2012-2013, bringing her cumulative total to over 11,000 citations. She and her 150 trainees contributed to more than 40 issued or pending patents (cancer nanotechnology, regenerative medicine, bioMEMS), 21 licensed products, and launched 9 biotechnology companies including Hepregen, Zymera, Sienna, Cell2B, and Seres. She consults for industry, government and academic organizations, and has been asked to serve on Harold Varmus’ Board of Scientific Advisors to the National Cancer Institute, Francis Collins’ National Institute of Health Working Group on Diversity, and Eric Lander’s Broad Institute Strategic Advisory Committee. Dr. Bhatia has spoken about the role of nanotechnology at the World Economic Forum, and in the last year alone she gave over 40 invited talks, including at John’s Hopkins, Nature Biotechnology, Sanofi, and the Gates Foundation, and delivered the NIH NIBIB Lecture at the National Biomedical Engineering Society Meeting and a Keynote lecture at the Gates Grand Challenges Meeting. Her work has been profiled broadly, such as in Scientific American, Popular Science, Forbes, HHMI Bulletin, PBS’s NOVA scienceNOW, and MSNBC. She has received multiple honors such as the NSF CAREER Award, and made top “Watch” lists at The Scientist, and MIT Technology Review, among others, and was recently named one of the “10 Most Influential Women in Biotech” by the Boston Globe. She is an elected Fellow of the Massachusetts Academy of Sciences, American Institute for Medical and Biological Engineering, and American Society for Clinical Investigation.
Peter Sorger, PhD
Otto Krayer Professor in the Department of Systems Biology at Harvard Medical School (HMS)
Visiting Professor of Biological Engineering at MIT
Peter Sorger is the Otto Krayer Professor in the Department of Systems Biology at Harvard Medical School (HMS) and Visiting Professor of Biological Engineering at MIT. Sorger was recently appointed as the founding head of the Harvard Program in Therapeutic Science (HiTS). In this role he leads a University-wide effort to advance the basic and clinical science used to develop drugs, therapeutic devices and cells, to evaluate their effectiveness through clinical trials and to identify those patients who are most likely to benefit. He is also the Director of the Laboratory of Systems Pharmacology (LSP), the flagship research activity in HiTS. The LSP opened in September 2013 and will move to a permanent, custom-designed facility in 2014 where it will support scientists from HMS, Harvard-affiliated hospitals and MIT.
Sorger’s research combines computational and experimental approaches to understanding signaling networks in normal and diseased cells, with an emphasis on cancer and inflammation. The Sorger lab develops new algorithms and software for modeling disease pathways. These models combine detailed molecular descriptions of individual genes (or drug targets) with systems-level understanding of the networks in which disease genes function. The models are tested using a combination of single-cell and intravital imaging, genetic and chemical perturbation and high-throughput molecular analysis of human cells and genetically engineered mice. Sorger’s goal is to create the “computational equivalents” of disease processes needed to effectively harness modern digital technologies for interpreting rapidly growing disease databases; such understanding is essential for the development of precision (personalized) medicine.
Sorger graduated from Harvard College in 1983, obtained his Ph.D. in biochemistry from Trinity College Cambridge in 1988, U.K, and trained as a Lucille P. Markey postdoctoral fellow with Harold Varmus at the University of California, San Francisco. As an assistant, associate and then full professor at MIT he studied cell cycle control, chromosome segregation and systems approaches to mammalian signaling transduction. Sorger is co-founder of the Open Microscopy Environment (OME), MIT’s Computational and Systems Biology Initiative (CSBi) and the Council for Systems Biology in Boston (CSB2; www.csb2.org). Sorger is co-founder of Merrimack Pharmaceuticals and Glencoe Software and an advisor to multiple public and private companies. He recently authored a definitive report on Systems Pharmacology for the National Institutes of Health (published in 2011).
Isaac T. Kohlberg
Senior Associate Provost
Chief Technology Development Officer, Harvard University
Isaac joined OTD in 2005, as Chief Technology Officer and Senior Associate Provost. Prior to joining Harvard, he served (from 1989 to 2000) as Vice Provost of New York University and Vice Dean for Industrial Liaison and Research Administration at the New York University School of Medicine. Most recently, Isaac was Chief Executive Officer of the Tel Aviv University Economic Corporation and CEO of RAMOT, its technology transfer organization. Isaac was also CEO of the YEDA Research and Development Company, the technology transfer company of the Weizmann Institute of Science, for eight years. He received his LLB from Tel Aviv University and his MBA from INSEAD, Fontainebleau, France.
Guest of Honor
Louis G. Lange, M.D., Ph.D.
Partner, Asset Management Company
Dr. Lange has 22 years experience in academic medicine at Harvard and Washington University, where he served as Chief of Cardiology and Professor of Medicine at Jewish Hospital from 1985-1992 and was one of the first academicians in molecular cardiology.
He founded CV Therapeutics based on this broad field and as Chairman, CEO and Chief Scientific Officer, led the IPO in 1996 and the overall pipeline development and the initiatives for US FDA and European EMEA approval for Ranexa®, a first-in-class late sodium channel blocker and the first anti-anginal drug class approved in 30 years in the US. He also led the approval of Lexiscan®, a first-in-class adenosine A2a receptor agonist for use in myocardial perfusion imaging studies. Dr. Lange oversaw the commercial success of CV Therapeutics and its sale to Gilead in 2009 for $1.4 billion dollars.
As a member of the Board of Trustees at the University of Rochester since 1998 and as Chair of the Health Affairs committee that oversees all of the medical operations for five years, Dr. Lange has been part of the leadership team for strategic re-invigoration of the medical center with construction of two research buildings and recruitment of over 100 faculty members. As a member of BIO Board of Directors (the trade organization of biotech companies) from 1999 to 2009, Dr. Lange led the largest committee of member companies for two years and was picked as one of two biotech executives to attend the ceremonies at the White House for the signing of the Bioterrorism bill in 2004. Dr. Lange has been on numerous other public and private Boards in both the non-profit and for-profit arena.
January 9, 2014